Impact of SGLT2 Inhibitors on Renal Function in Patients with Heart Failure: a systematic review and meta-analysis
In brief
SGLT2 drugs cut kidney events 28%, acute kidney injury 25% in heart failure
In a meta-analysis of 13 trials, SGLT2 inhibitors reduced composite kidney events by 28% and acute kidney injury by 25% among patients with heart failure, followed for a median of 2.3 years. Benefits were similar across baseline kidney function groups, but the analysis does not resolve how to manage an early dip in kidney function during treatment.
- Journal
- ESC heart failure (Q1)
- Published
- 19 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Akshat Sinha, Nimai Desai, Ramesh Nadarajah, Francisco Levya, Peysh A Patel
- PMID
- 43056248
- DOI
- 10.1093/eschf/xvag288
Why clinicians should know about it
- Picked for Nephrology (top studies of the week, 22 November 2026): Meta-analysis reports SGLT2 inhibitor renal outcomes and AKI
- Picked for Cardiology and Cardiovascular Medicine (paper of the day, 20 November 2026): Meta-analysis assesses renal benefits of SGLT2 inhibitors in HF
Abstract
AIMS: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an integral part of heart failure (HF) therapy. The purpose of this study was to elucidate the effect of SGLT2 inhibitors on renal function, in HF patients, over longer-term follow-up. This could be compared to existing data in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus T2DM. METHODS: A systematic review and meta-analysis was conducted in patients with HF treated with SGLT2 inhibitor (PROSPERO ID: CRD42024562311). Searches were performed across five databases from inception to 31 October 2024 identifying randomised controlled trials. Included studies were appraised using the Cochrane Risk of Bias tool. Two primary outcomes were investigated, composite renal event and AKI (acute kidney injury). Relative risk (RR) was pooled with 95% CI using the statistical software 'R'. RESULTS: Thirteen trials involving 90,413 participants were included. Median follow-up was 2.3 years, and data of 32,957 patients with HF was extracted. In patients with HF, SGLT2 inhibition reduced renal specific composite outcomes by 28% (RR 0.72; 95% CI 0.57-0.91). Additionally, AKI was reduced in HF patients taking SGLT2 inhibitors (RR 0.75; 95% CI 0.65-0.86). Subgroup analysis showed no differences in patients with and without HF, or when stratified by baseline renal function. CONCLUSION: These results encourage use of SGLT2 inhibitors to retard progression of kidney disease and AKI. This benefit was seen in all trials, irrespective of concurrent comorbidities. Despite the acute dip in eGFR, SGLT2 inhibitors should be continued to maximise benefit, even in patients with HF.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.